Abstract:Question What outcome measurement instruments are recommended to measure clinical signs in patients with atopic dermatitis (AD) in clinical practice? Findings After a consensus process informed by systematic reviews, the Eczema Area and Severity Index, the Validated Investigator Global Assessment for Atopic Dermatitis, and the Investigator's Global Assessment multiplied by or measured concurrently with a body surface area assessment were recommended to measure clinical signs of AD in clinical practice. Meaning It is recommended that clinicians incorporate at least 1 of these feasible, validated instruments into their care of patients with AD in clinical practice and in their electronic health documentation to enhance clinical care and support empirical evidence generation, value-based health care, and quality-of-care assessments. Importance Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical Practice initiative aims to identify a list of validated, feasible, outcome measurement instruments recommended to measure atopic dermatitis (AD) in the clinical practice setting. The clinical practice set is a list of instruments that clinicians can pick and choose from to suit their needs in the context of clinical care. Objective To recommend instruments to measure clinical signs of AD in clinical practice. Evidence Review Following the predefined roadmap, a mixed methods design was implemented and incorporated systematic reviews and qualitative consensus methods. Previous systematic reviews identified few clinical signs instruments with sufficient validation for recommendation. An updated systematic review evaluating the validity of clinical signs instruments informed an international meeting to reach consensus on recommended instruments to measure AD clinical signs in clinical practice. Consensus was defined as less than 30% disagreement. An in-person consensus exercise was held in Montreal, Canada, on October 16, 2022. The 34 attendees included patient and patient advocate research partners, health care professionals, researchers, methodologists, and industry representatives. Findings The updated systematic review found that the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis, and objective Scoring Atopic Dermatitis were the only instruments that demonstrated sufficient performance in all assessed measurement properties. The modified EASI and Signs Global Assessment × Body Surface Area instruments were also recommended. The EASI, Validated Investigator Global Assessment, and Investigator's Global Assessment multiplied by or measured concurrently with a body surface area measure achieved consensus in criteria and were adopted. Conclusions and Relevance This consensus statement by the Harmonising Outcome Measures for Eczema initiative suggests that when assessing and documenting clinical signs of AD, there are several valid and feasible instruments that can best fit a clinician's specific practice needs. These instruments should improve and standardize the documentation of signs severity, help determine the effect of treatment, facilitate the generation of clinical effectiveness evidence, and enhance the implementation of value-based health care.

[Translated article] Patient-reported outcome measures for assessing atopic dermatitis in clinical practice

Measuring Signs of Atopic Dermatitis in Clinical Practice

Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria Are Underused in Clinical Practice

Correlation between disease severity indices and quality of life measurement tools in atopic dermatitis patients

The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use

[Translated article] Real-World Clinical, Psychosocial and Financial Burden of Atopic Dermatitis: Results from the Spanish Cohort of the MEASURE-AD Trial

Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review

Patient-reported burden in adults with atopic dermatitis: an international qualitative study

Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis

Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis

Assessing top quality of life measures in Acne Vulgaris studies: a crucial dimension in patient-centric care

Ringing in the Patient Voice: Measuring Patients Lived Experience of Dermatomyositis Symptoms

P05 Pre-visit online paediatric atopic dermatitis questionnaire – a feasibility study

[Health services research the example of atopic dermatitis]

Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes

Content Evaluation of Pruritus, Skin Pain, and Sleep Disturbance Patient-Reported Outcome Measures in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Qualitative Interviews

Quality of Care and Management of Atopic Dermatitis Across Different Levels of Healthcare-A Survey-Based Patient Experience

Validating Patient-Reported Outcome Measures in Dermatology

405 Understanding patient experience and factors influencing patient preference in the treatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews

Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care

Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families